Multi-cohort high-dimensional proteomics reveals early risk markers for lymphoid cancer subtypes

dc.contributor.authorMartijn Kolijn, P.
dc.contributor.authorSmith-Byrne, Karl
dc.contributor.authorBurk, Vernon
dc.contributor.authorViallon, Vivian
dc.contributor.authorLee, Matthew A.
dc.contributor.authorPapier, Keren
dc.contributor.authorWang, Ziqiao
dc.contributor.authorLangerak, Anton W.
dc.contributor.authorSpäth, Florentin
dc.contributor.authorDiepstra, Arjan
dc.contributor.authorLill, Christina M.
dc.contributor.authorZamora-Ros, Raul
dc.contributor.authorMacciotta, Alessandra
dc.contributor.authorAizpurua, Amaia
dc.contributor.authorTumino, Rosario
dc.contributor.authorChatterjee, Nilanjan
dc.contributor.authorTravis, Ruth C.
dc.contributor.authorGunter, Marc J.
dc.contributor.authorPlatz, Elizabeth A.
dc.contributor.authorRiboli, Elio
dc.contributor.authorMckay, James
dc.contributor.authorVermeulen, Roel C. H.
dc.date.accessioned2025-11-28T12:32:19Z
dc.date.available2025-11-28T12:32:19Z
dc.date.issued2025-10-28
dc.date.updated2025-11-26T15:49:40Z
dc.description.abstractThis study aims to investigate the early stages of lymphoid malignancy pathogenesis and identify pre-diagnostic proteomic markers for lymphoma. Using the SomaScan-7K platform, we analyze 6412 unique plasma proteins in a case-cohort study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, comprising 4565 participants (484 incident lymphoid malignancy cases, median follow-up 9 years). We identify over 500 unique protein-lymphoid malignancy associations. Enriched pathways include viral protein interactions, cytokine signaling, B-cell receptor signaling, and NF-kappa B activation, reflecting key mechanisms in lymphoma pathogenesis. Cross-cohort validation of the top 20 FDR-significant proteins reveals concordant nominal significance for 70%-95% of the associations in the UK Biobank (Olink) and ARIC (SomaScan) studies. Time-stratified analyses reveals that a subset of these protein-lymphoma associations is evident over a decade before diagnosis. These findings highlight the potential of circulating proteomic markers in risk stratification, early diagnosis, and targeted prevention strategies for lymphoid malignancies.
dc.format.extent14 p.
dc.format.mimetypeapplication/pdf
dc.identifier.issn2041-1723
dc.identifier.pmid41152224
dc.identifier.urihttps://hdl.handle.net/2445/224497
dc.language.isoeng
dc.publisherSpringer Science and Business Media LLC
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1038/s41467-025-64534-4
dc.relation.ispartofNature Communications, 2025, vol. 16, 9517
dc.relation.urihttps://doi.org/10.1038/s41467-025-64534-4
dc.rightscc-by (c) Martijn Kolijn, P. et al., 2025
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subject.classificationAnàlisi de pèptids
dc.subject.classificationPatologia molecular
dc.subject.classificationMarcadors tumorals
dc.subject.otherAnalysis of peptides
dc.subject.otherMolecular pathology
dc.subject.otherTumor markers
dc.titleMulti-cohort high-dimensional proteomics reveals early risk markers for lymphoid cancer subtypes
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
s41467-025-64534-4.pdf
Mida:
1.27 MB
Format:
Adobe Portable Document Format